What is Theraclone Sciences?
Theraclone Sciences is a biotechnology firm dedicated to the rapid identification of rare human monoclonal antibodies. These antibodies are engineered to combat infections and treat a spectrum of diseases. Leveraging over a decade of expertise, the company has refined a comprehensive screening technology crucial for therapeutic product development. Theraclone Sciences has demonstrated its platform's value through strategic licensing agreements, including its HIV broadly neutralizing fully-human antibodies to Gilead for an HIV-cure regimen and its platform technology to OncoResponse for oncology applications. The company primarily serves clients within the pharmaceutical and biotechnology sectors, positioning itself as a key player in antibody discovery and development.
How much funding has Theraclone Sciences raised?
Theraclone Sciences has raised a total of $35.5M across 4 funding rounds:
Series A
$2M
Series B
$29M
Unspecified
$1.5M
Private Equity
$3.1M
Series A (2004): $2M, investors not publicly disclosed
Series B (2007): $29M led by MPM Capital, HealthCare Ventures, ARCH Venture Partners, Amgen Business Development, Alexandria Real Estate Equities, and Canaan Partners
Unspecified (2010): $1.5M supported by Amgen Business Development, MPM Capital, Canaan Partners, ARCH Venture Partners, Healthcare Ventures, and Alexandria Real Estate Equities
Private Equity (2015): $3.1M, investors not publicly disclosed
Key Investors in Theraclone Sciences
MPM Capital
MPM BioImpact manages early-stage venture funds, private/public impact funds and a public equities fund. We convert science into therapeutics to reach the patients that need them most.
ARCH Venture Partners
ARCH Venture Partners is a leading earlystage venture capital firm that creates and invests in life sciences and advanced technology companies, often cofounding startups with scientists and entrepreneurs to commercialize innovations from universities, corporate R&D groups, and national laboratories.
Canaan Partners
Canaan is an early-stage venture capital firm that invests in technology and healthcare companies, backing founders from seed through growth stages in areas such as enterprise software, fintech, consumer, biopharma, and digital health. With offices in the U.S. and Israel and billions of dollars under management, Canaan has funded hundreds of startups and supported dozens of IPOs and acquisitions.
What's next for Theraclone Sciences?
The substantial enterprise-level investment and recent strategic financing indicate Theraclone Sciences is poised for accelerated growth and the expansion of its therapeutic pipeline. This capital infusion will likely fuel further research and development, potentially leading to new clinical trials and broader market penetration for its antibody-based treatments. The company's established partnerships with major pharmaceutical entities suggest a strategic focus on advancing its licensed technologies towards commercialization, solidifying its position in the competitive landscape of infectious disease and oncology therapeutics.
See full Theraclone Sciences company page
